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ABSTRACT 
Background and aims: fecal microbiota transplantation 
(FMT) is effective for recurrent Clostridium difficile infec-
tion (CDI). Intestinal decolonization of carbapenamase-pro-
ducing enterobacteriaceae (CPE) can prevent transmission 
and infection by these agents. The aim of this study was to 
assess CPE decolonization after FMT.
Methods: this was a case-series study that consecutively 
included all CPE-carriers that underwent FMT between 2014 
and 2019. The indications included refractory/recurrent CDI 
and CPE-decolonization.
Results: out of 21 CPE-carriers, eight were excluded due to 
incomplete post-FMT testing. CPE decolonization was con-
firmed in 76.9 % (n = 10). The median decolonization time 
was 16-weeks (IQR-23) and ranged from two to 53 weeks.
Conclusion: FMT may be used in the clinical practice for 
CPE-decolonization as an alternative to combined antibiotic 
regimens.
Keywords: Fecal microbiota transplantation. Carbape-
namase-producing enterobacteriaceae. Multidrug-resistant 
infections. Decolonization. Intestinal carriage.
INTRODUCTION
Fecal microbiota transplantation (FMT) has been shown 
to be more effective and durable than standard treatment 
protocols for recurrent Clostridium difficile infection (CDI), 
reaching a success rate of up to 95 % (1-3). Furthermore, 
several other areas of potential interest for application 
have been highlighted, namely inflammatory bowel dis-
ease, irritable bowel syndrome, hepatic encephalopathy 
and eradication of multidrug-resistant (MDR) microorgan-
isms (1). Intestinal colonization by carbapenamase-pro-
ducing enterobacteriaceae (CPE) has been increasingly 
reported (4-7). It is estimated that 10 % of patients will 
develop CPE infections, which are often associated with 
treatment failure and mortality rates higher than 50 % 
(8,9). CPE decolonization can prevent transmission and 
infection by these agents. Thus, FMT may be a potential 
alternative to currently used combined antibiotic regi-
mens (10). 
The aim of this study was to assess the CPE carrier sta-
tus after-FMT in a population of patients colonized by CPE 
undergoing FMT.
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Patient selection and data collection
A retrospective analysis was performed in a cohort of 
patients who underwent FMT between June, 2014 and 
October, 2019 in our department. The study protocol was 
approved for the following indications: refractory CDI, 
recurrent CDI and CPE decolonization. Patients older than 
18 years with positive CPE screening prior to FMT and no 
immunosuppressive conditions were included. Patients 
without screening for CPE intestinal colonization after 
FMT or without follow-up were excluded. CPE colonization 
was considered as the presence of ≥ 1 positive test for CPE 
through molecular biology or culture techniques. 
FMT protocol
The institutional protocol for FMT used was developed to 
standardize the criteria of recipients, donors and the proce-
dure itself (3). Donors were unrelated volunteers selected 
and screened based on medical history and laboratory test-
ing, as detailed in our unit protocol (3). All patients under-
went bowel preparation (4l-polyethyleneglycol) the night 
before the procedure. Proton-pump inhibitors were given 
to the recipient the evening before and the morning of the 
procedure. 
All CDI patients maintained the antibiotic prescription until 
the day before the FMT. The initial CDI episode treatment 
included vancomycin, fidaxomicin or metronidazole. For 
recurrent CDI, a pulsed/tapered vancomycin regimen, a ten-
day course of fidaxomicin or a standard course of vanco-
mycin (if metronidazole was used for the primary episode) 
were used (2). No patients underwent combined antibiotic 
therapy for CDI nor CPE decolonization.
FMT procedures were performed by esophagogastroduo-
denoscopy (EGD) with progression to the distal duodenum, 
where 50 cc of a processed suspension of fresh stool from 
an unrelated donor collected between 4-24 hours before 
the procedure was delivered. Patients were followed-up in 
order to monitor FMT-related adverse events. No antibiotic 
treatment was administered after FMT.
CPE colonization testing and post-FMT follow-up
Testing for CPE colonization was performed by two meth-
odologies according to our institution protocol. On hospital 
admission, patients at risk of MDR infections were screened 
for CPE colonization via molecular biology techniques in 
a rectal swab. Screening was performed by culture of a 
rectal swab sample in the outpatient setting as well as in 
hospitalized patients.
After FMT, patients were contacted by the Infection Control 
Group for ambulatory CPE testing. Recruitment and test-
ing intervals were conditioned by local resources and the 
patient’s functional condition. The authors further recruited 
patients who were lost to follow-up for CPE testing. Decol-
onization was assumed when three consecutive negative 
screening tests were obtained with at least a one-week 
interval between them. CPE eradication was not considered 
in patients with < 3 or nonconsecutive negative screenings 
after FMT.
Statistical analysis
The Statistical Package for Social Sciences (SPSS) program 
version 26 was used. Categorical variables are summarized 
as frequencies and percentages. The Chi-squared test or 
Fisher’s exact test was used to compare categorical vari-
ables. Continuous variables were expressed as the mean 
(μ) and standard deviation (SD) or median and interquartile 
range (IQR). 
RESULTS
Figure 1 summarizes patient selection and clinical out-
comes according to FMT indication. Forty-nine procedures 
were performed in our unit between June, 2015 and June, 
2019. Out of 21 CPE-carriers that underwent FMT, eight 
were excluded due to loss of follow-up after FMT. Sub-
sequently, 13 patients were included, 61.5 % were female 
(n = 8), with a mean age of 61.8 ± 21.0 years. In all cases, 
FMT was performed by EGD. No procedure-related com-
plications were reported. Refractory/recurrent CDI was the 
indication in 61.5 % (n = 8). FMT lead to CDI cure defined 
as the resolution of diarrhea within two months after the 
procedure in all cases. CPE decolonization was the indica-
tion for FMT in the remaining 38.5 % (n = 5).
CPE decolonization was confirmed in 76.9 % (n = 10) 
(Table 1). Globally, the decolonization rate in our cohort of 
21 CPE-carriers was 47.6 % (n = 10). The median decoloni-
zation time was 16-weeks (IQR 23) and ranged from two to 
53 weeks. Regarding indication, decolonization occurred 
in 75.0 % (n = 6) when FMT was performed due to refrac-
tory/recurrent CDI and in 80.0 % (n = 4) when primary CPE 
decolonization motivated the procedure (p = 0.685). No 
patient developed CPE infections.
DISCUSSION
In this case series, CPE decolonization after FMT reached 
a success rate of 76.9 %. Thus, FMT may be used in the 
clinical practice for MDR decontamination and as a public 
health intervention to minimize cases of severe and refrac-
tory infections caused by those agents. The literature on 
FMT for CPE decolonization is scarce and mostly limited to 
case reports and small-uncontrolled studies (11). Saha S 
et al. performed a systematic review that mostly included 
case-reports and uncontrolled studies and reported an MDR 
eradication rate from 37.5 % to 87.5 %. Nonetheless, this 
review included different patient populations, MDR agents, 
microbiological techniques and definitions of decoloniza-
tion. Thus, the evidence was also of low quality (12). Simi-
larly, Tavoukjian V et al. performed a systematic review and 
meta-analysis reporting decolonization rates up to 67.0 %. 
Nevertheless, patients with CDI were excluded and the defi-
nition of decolonization varied significantly (13).
Huttner et al. conducted a multicenter randomized con-
trolled trial (RCT) to assess a combined strategy of oral 
antibiotics followed by frozen FMT for CPE and/or extended 
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spectrum b-lactamases enterobacteriaceae (ESBL-E) decol-
onization. Non-absorbable antibiotics followed by FMT 
slightly decreased ESBL/CPE carriage (41 %) compared to 
controls (29 %). However, this difference was not statisti-
cally significant, potentially due to early trial-termination 
and a failure to achieve the planned sample size (14).
49 FMT
13 Included 8 Excluded
21 CPE-carriers
Recurrent CDI, n = 5
Refractory CDI, n = 11
CPE decolonization, n = 5
CDI cure
100 % (n = 8)
CPE decolonization
75 % (n = 6)
CPE decolonization
80 % (n = 4)
Death related to other medical conditions 
before follow-up
CPE testing (n = 6)
Unable to take CPE testing due to severe 
functional impairment related to medical 
comorbidities (n = 2)
CPE decolonization
77 % (n = 10)
Without screening for CPE intestinal 
colonization after FMT or without follow up
Recurrent CDI, n = 3
Refractory CDI, n = 5
CPE decolonization, 
n = 5
Fig. 1. Patient selection and clinical outcomes according to FMT indication (CPE: carbapenamase-producing 
enterobacteriaceae; FMT: fecal microbiota transplantation; CDI: Clostridium difficile infection).
Table 1. Characterization of patients with decolonization of CPE after FMT
No. of patients
(n = 11)




Time to 3rd negative 
screening
(weeks)
Patient 1 66 Female Recurrent CDI EGD Yes 17
Patient 2 87 Male Refractory CDI EGD No
Patient 3 71 Female Refractory CDI EGD Yes 14
Patient 4 70 Female Recurrent CDI EGD Yes 4
Patient 5 64 Male Recurrent CDI EGD Yes 18
Patient 6 79 Female Refractory CDI EGD No
Patient 7 21 Female CPE decolonization EGD Yes 2
Patient 8 27 Female CPE decolonization EGD Yes 53
Patient 9 55 Male CPE decolonization EGD Yes 28
Patient 10 46 Female CPE decolonization EGD Yes 12
Patient 11 51 Male CPE decolonization EGD No
Patient 12 80 Male Refractory CDI EGD Yes 6
Patient 13 86 Female Refractory CDI EGD Yes 31
CPE: carbapenamase-producing enterobacteriaceae; FMT: fecal microbiota transplantation; CDI: Clostridium difficile infection; EGD: esophagogastroduodenoscopy; yr: years.
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Our study has several limitations. Due to high morbimortal-
ity secondary to medical comorbidities, 38 % of CPE carri-
ers were not submitted to screening after FMT. Moreover, 
recruitment and testing intervals after FMT were condi-
tioned by the patient’s characteristics and local resources. 
Time to decolonization varied widely due to follow-up pro-
tocol heterogeneity. Prompt and systematic testing after 
FMT according to a rigorous predefined protocol might 
mitigate the number of lost patients in further studies. Fur-
thermore, spontaneous decolonization was not evaluated, 
even though the evidence suggests that it occurs later and 
less often (13).
Although this and other case studies do not constitute suf-
ficient evidence to recommend the routine use of FMT in 
patients colonized by MDR agents, it reinforces the con-
cept of post-FMT CPE decolonization. Currently, there are 
several clinical trials underway due to the urgent need for 
high-quality prospective data and a consensus definition 
for decolonization.
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